{"organizations": [], "uuid": "0f9c278c4d1e046b28a6970eac1b56fd3e835f81", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-eli-lilly-and-co-q4-non-gaap-earni/brief-eli-lilly-and-co-q4-non-gaap-earnings-per-share-1-14-idUSL8N1PQ3YC", "country": "US", "domain_rank": 408, "title": "BRIEF-Eli Lilly And Co Q4 Non-GAAP Earnings Per Share $1.14", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-01-31T14:18:00.000+02:00", "replies_count": 0, "uuid": "0f9c278c4d1e046b28a6970eac1b56fd3e835f81"}, "author": "", "url": "https://www.reuters.com/article/brief-eli-lilly-and-co-q4-non-gaap-earni/brief-eli-lilly-and-co-q4-non-gaap-earnings-per-share-1-14-idUSL8N1PQ3YC", "ord_in_thread": 0, "title": "BRIEF-Eli Lilly And Co Q4 Non-GAAP Earnings Per Share $1.14", "locations": [], "entities": {"persons": [], "locations": [{"name": "u.s.", "sentiment": "none"}, {"name": "cymbalta", "sentiment": "none"}], "organizations": [{"name": "brief-eli lilly and co", "sentiment": "negative"}, {"name": "reuters", "sentiment": "none"}, {"name": "thomson reuters", "sentiment": "none"}, {"name": "eli lilly and co", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "January 31, 2018 / 12:19 PM / in 4 minutes BRIEF-Eli Lilly And Co Q4 Non-GAAP Earnings Per Share $1.14 Reuters Staff \nJan 31 (Reuters) - Eli Lilly And Co: \n* LILLY REPORTS STRONG FOURTH-QUARTER AND FULL-YEAR 2017 REVENUE GROWTH, INCREASES 2018 EPS GUIDANCE * Q4 NON-GAAP EARNINGS PER SHARE $1.14 \n* Q4 EARNINGS PER SHARE VIEW $1.07 -- THOMSON REUTERS I/B/E/S \n* SEES FY 2018 EARNINGS PER SHARE $4.39 TO $4.49 INCLUDING ITEMS * Q4 LOSS PER SHARE $1.58 \n* FOR Q4 2017, ALIMTA GENERATED WORLDWIDE REVENUE OF $525.2 MILLION, WHICH DECREASED 3 PERCENT \n* ELI LILLY - RECORDED ESTIMATED CHARGE OF $1.9 BILLION IN QUARTER ASSOCIATED WITH U.S. TAX REFORM LEGISLATION, CHARGES ASSOCIATED WITH REDUCING COST STRUCTURE * QTRLY REVENUE $6,160.7 MILLION VERSUS $5,760.5 MILLION * Q4 REVENUE VIEW $5.93 BILLION -- THOMSON REUTERS I/B/E/S * SEES 2018 ADJUSTED EARNINGS PER SHARE $4.81 TO $4.91 \n* QTRLY JARDIANCE SALES $143.2 MILLION VERSUS $76.1 MILLION \n* COMPANY STILL ANTICIPATES 2018 REVENUE BETWEEN $23.0 BILLION AND $23.5 BILLION \n* SAYS QTRLY CYMBALTA SALES $192.8 MILLION VERSUS $181.8 MILLION \n* FY2018 EARNINGS PER SHARE VIEW $4.68, REVENUE VIEW $23.21 BILLION -- THOMSON REUTERS I/B/E/S * QTRLY REPORTED LOSS PER SHARE $1.58 \n* ELI LILLY - 2018 REV GROWTH EXPECTED TO BE DRIVEN BY NEW PRODUCTS INCLUDING TRULICITY, TALTZ, BASAGLAR, JARDIANCE, VERZENIO, CYRAMZA, OLUMIANT, LARTRUVO \n* ELI LILLY AND CO - DURING 2017, CO RECORDED INCOME TAX EXPENSE OF $2.402 BLN, WHICH INCLUDED AN ESTIMATED TAX CHARGE OF $1.914 BLN Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-01-31T14:18:00.000+02:00", "crawled": "2018-01-31T14:36:52.008+02:00", "highlightTitle": ""}